In The News

In The Newsalzheon2023-03-24T11:15:08-04:00

In the News

Beginning a New Era of Precision Alzheimer’s Therapeutics

Inside Precision Medicine

Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc. January 2024

Newsweek Investment Reports

ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s

Alzheimer's News Today

Alzheimer Agent ALZ-801 Improves Cognition, Reduces Relevant Biomarker Levels in 2-Year Analysis

neurologylive.com

AAIC: A Pill to Slow Down Alzheimer’s Is About Two Years Away

beingpatient.com

Venture Capitalists Fund New Generation of Alzheimer’s Drugs

WSJ

Understanding Patient Characteristics of Phase 3 APOLLOE4 Trial of ALZ-801 in Alzheimer Disease: John Hey, PhD

NeurologyLive

Eli Lilly’s Donanemab: The Anti-Amyloid Saga Continues

Seeking Alpha

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact